• Absci outlined strategy built around generative AI with an integrated, automated 77,000-square-foot wet lab aimed at shortening antibody discovery cycles to about six weeks.
• Lead program ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, remains on track for an accelerated Phase 1/2a study with interim proof-of-concept data expected in 2H 2026.
• Program expansion into endometriosis targets Phase 2 start in 4Q 2026 with proof-of-concept data as early as 2H 2027.
• Absci highlighted ABS-101 for inflammatory bowel disease as ready for partnering, citing improved half-life and tissue penetration versus first-generation TL1a molecules.
• Presentation framed platform economics as about $10 million to $15 million and roughly 24 months to reach candidates, versus $50 million to $100 million and 5 to 6 years for large pharma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.